Inventor · disambiguated record
Albert Amegadzie
Also filed as: AMEGADZIE ALBERT · AMEGADZIE ALBERT K · AMEGADZIE ALBERT KUDZOVI
31 granted patents·11 pending applications·338 citations·filing 2003–2025
97Inventor score
Top patents by PatentIndex Score
42 records- 0198US11766436B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2021·Granted Sep 26, 2023·11 cites·19 claims
- 0298US11090304B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Aug 17, 2021·33 cites·3 claims
- 0397US11045484B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Jun 29, 2021·24 cites·34 claims
- 0496US12083121B2Substituted piperazines as KRAS G12C inhibitorsAMGEN INC·Filed 2022·Granted Sep 10, 2024·7 cites·5 claims
- 0596US11285156B2Substituted piperazines as KRAS G12C inhibitorsAMGEN INC·Filed 2019·Granted Mar 29, 2022·16 cites·4 claims
- 0696US9611261B2Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2015·Granted Apr 4, 2017·25 cites·40 claims
- 0795US11827635B2Solid state formsAMGEN INC·Filed 2021·Granted Nov 28, 2023·11 cites·16 claims
- 0895US11236091B2Solid state formsAMGEN INC·Filed 2020·Granted Feb 1, 2022·21 cites·25 claims
- 0995US9085576B2Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2014·Granted Jul 21, 2015·31 cites·60 claims
- 1094US8426447B2Spiro-tricyclic ring compounds as beta-secretase modulators and methods of useWHITE RYAN·Filed 2009·Granted Apr 23, 2013·58 cites·22 claims
- 1193US12440491B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2023·Granted Oct 14, 2025·1 cites·4 claims
- 1290US12398133B2Solid state formsAMGEN INC·Filed 2023·Granted Aug 26, 2025·1 cites·42 claims
- 1389US7538114B2Glycine transporter-1 inhibitorsAMGEN INC·Filed 2007·Granted May 26, 2009·14 cites·43 claims
- 1488US2025381187A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2025·Application pending·0 cites
- 1586US12421234B1Solid state formsAMGEN INC·Filed 2025·Granted Sep 23, 2025·0 cites·29 claims
- 1686US12415806B1Solid state formsAMGEN INC·Filed 2025·Granted Sep 16, 2025·0 cites·22 claims
- 1786US7179804B2Tachykinin receptor antagonistsLILLY CO ELI·Filed 2003·Granted Feb 20, 2007·30 cites·18 claims
- 1885US7320994B2Triazole derivatives as tachykinin receptor antagonistsLILLY CO ELI·Filed 2003·Granted Jan 22, 2008·28 cites·34 claims
- 1983US7595339B2CB1 modulator compoundsLILLY CO ELI·Filed 2007·Granted Sep 29, 2009·6 cites·2 claims
- 2080US7902356B2Thiazolopyridinone derivates as MCH receptor antagonistsLILLY CO ELI·Filed 2005·Granted Mar 8, 2011·6 cites·11 claims
- 2178US9174992B2Heterobicyclic compoundsAMGEN INC·Filed 2013·Granted Nov 3, 2015·4 cites·17 claims
- 2276US8883782B2Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of useCHENG YUAN·Filed 2011·Granted Nov 11, 2014·4 cites·18 claims
- 2376US2025304599A1Macrocyclic compounds and methods of useAMGEN INC·Filed 2024·Application pending·0 cites
- 2469US9550762B2Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2015·Granted Jan 24, 2017·1 cites·95 claims
- 2569US7276516B2CB1 antagonist compoundsLILLY CO ELI·Filed 2004·Granted Oct 2, 2007·5 cites·13 claims
- 2669US2025236631A1Macrocyclic compounds and methods of useAMGEN INC·Filed 2025·Application pending·0 cites
- 2766US8258306B2Glycine transporter-1 inhibitorsHITCHCOCK STEPHEN A·Filed 2008·Granted Sep 4, 2012·1 cites·11 claims
- 2865US8183244B2Glycine transporter-1 inhibitorsHITCHCOCK STEPHEN·Filed 2009·Granted May 22, 2012·0 cites·35 claims
- 2965US2024409557A15,6-fused and 6,6-fused bicyclic alcohols and ethers and compositions for use as 15-prostaglandin dehydrogenase modulatorsAMGEN INC·Filed 2024·Application pending·0 cites
- 3062US9663476B2Glycine transporter-1 inhibitorsAMGEN INC·Filed 2014·Granted May 30, 2017·0 cites·20 claims
- 3154US2024124442A1Tricyclic-amido-bicyclic prmt5 inhibitorsAMGEN INC·Filed 2022·Application pending·0 cites
- 3252US12473289B2Heterocyclic compounds as delta-5 desaturase inhibitors and methods of useAMGEN INC·Filed 2020·Granted Nov 18, 2025·0 cites·10 claims
- 3352US2011166132A1Gamma Secretase ModulatorsAMGEN INC·Filed 2008·Application pending·0 cites
- 3452US2023159510A1Novel prmt5 inhibitorsAMGEN INC·Filed 2021·Application pending·0 cites
- 3552US2024101570A1Tricyclic carboxamide derivatives as prmt5 inhibitorsAMGEN INC·Filed 2021·Application pending·0 cites
- 3648US10889581B2Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2017·Granted Jan 12, 2021·0 cites·21 claims
- 3747US2015252011A1Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2015·Application pending·0 cites
- 3846US8735383B2Glycine transporter-1 inhibitorsSTEPHEN HITCHCOCK·Filed 2012·Granted May 27, 2014·0 cites·25 claims
- 3946US2017267673A1Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2016·Application pending·0 cites
- 4044US2006160794A1Tachykinin receptor antagonistsAMEGADZIE ALBERT K·Filed 2004·Application pending·0 cites
- 4138US10246429B2Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2016·Granted Apr 2, 2019·0 cites·54 claims
- 4237US8101764B2MCH receptor antagonistsAMEGADZIE ALBERT KUDZOVI·Filed 2007·Granted Jan 24, 2012·0 cites·14 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →